@EstesRadonc

Radiation oncologist in MO | @RadoncTables | Tweets = my own

Joined March 2020
  • Tweets207
  • Following346
  • Followers801
Is there a threshold of people who are putting their hand on the rock will eventually imbue conscious into it? I doubt it. AI is the same way. It’s a big statistical machine. However it has no unique physics or quantum input - and no actual sensory input
46
From one perspective, INSEMA and SOUND are poorly designed and underpowered clinical trials for RNI. SOUND authors themselves write in the discussion that the trial was not powered to detect differences from adjuvant treatments.
1
5
130
The INSEMA authors write that omission of SLNB was must be weighed against potential benefit of RNI. If RNI was a requirement in those with 1-3 nodes, and the trial was properly powered, EBCTCG 2023 suggests the results may have been different.
4
123
RTOG 1112 Median OS 15.8 vs. 12.3 mos Median PFS 9.2 vs. 5.5 mos TTP also improved Grade 3+ toxicity not different KEYNOTE-240 (pembro) Median OS 13.9 vs. 10.6 mos Median PFS 3.0 vs. 2.8 mos Grade 3 events 53% vs. 46% 2/3
1
4
STRIDE (tremelimumab + durvalumab) Median OS 16.4 vs. 13.8 mos 3-yr OS 31% vs. 20% Median PFS not different Grade 3-4 events similar Checkmate 459 (nivolumab) Median OS 16.4 vs. 14.7 mos 2-yr OS 37% vs. 33% Median PFS 3.7 vs. 3.8 mos 3/3
1
Lunch at #ASTRO22 from @towerofamericas @jryckman3 @radoncreview @_ShankarSiva @ShaneNeibart @EstesRadonc @ASTRO_org
2
1
21
Fun article from Jerome M Karp on why we're called radiation oncology, and the ins and outs of the grammar involved But if we change our name to radio-oncology, does that mean we like to listen to FM radios while treating cancer? DOI:doi.org/10.1016/j.prro.2022.…
3
TROG BIG published! 📌DCIS ➡️ 16 Gy boost 🏆 vs no boost 5-yr LC 97% vs 93% ➡️ Hypofx 🏆 vs conventional No diff in LC No differences on subanalysis by any factor, inc hypofx/conv thelancet.com/journals/lance…
1
26
2
65
more replies
Toxicity Grade 2+ breast pain 14% vs 10% Grade 2+ induration 14% vs 6% Might lead some to have caution, rx 10 Gy, or use SIB boost, or wait for longer f/u
3
5
Massive trial with 11 countries participating! Publication in Lancet. Potentially practice changing for many
6
🤖Until the robots do it for us, use #TG263.🤖 #MedPhys #RadOnc
8
15
5
119
Interesting propensity analysis from the STRASS authors comparing STRASS patients with a cohort of those not enrolled in the study, from same centers (“STREXIT” 🙅‍♂️) In the cohort, pre-op RT improved ARFS in well-differentiated liposarcoma and G1-2 dediff LPS ✅
This Post is from a suspended account. Learn more
1
2
2
⭐️RT for borderline pancreas on RadOnc Tables Two trials: CONKO-007 and Alliance ALLIANCE 📌 RT arm terminated early due to low R0 at n=30 patients. 📌 All pCRs were in RT arm even after full enrollment of chemo alone arm. Potentially underpowered jamanetwork.com/journals/jam…
1
6
8
more replies
ascopubs.org/doi/10.1200/JCO…

Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy...

4008Background: Chemotherapy (CT) is the standard of care in nonresectable locally advanced pancreatic cancer. The CONKO-007 trial studied the role of sequential CT and chemoradiotherapy (CRT)....

ascopubs.org
1
1
Summary: 📌 In both trials, the only pCRs were in the RT arms 📌 RT may improve LC, R0, and pCR rates 📌 Potential role for RT in borderline pancreas
3
Load more